loader
Mankind Pharma Limited
Issue Size (Net)
up to Rs.4326.36 Cr
Price Band
1026 to 1080 per share
Issue Opens
25-Apr-23
Issue Closes
27-Apr-23

Company Highlights

1.Company Information

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.

In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.

It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.

Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market ("IPM"). Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.

The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.

2. Objective of the Issue
The Company proposes to utilize the Net Proceeds towards funding of the following objects:

All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.

Mankind Pharma IPO Registrar
KFin Technologies Limited

Phone:04067162222, 04079611000

Email: mankind.ipo@kfintech.com

Website: https://karisma.kfintech.com/

Mankind Pharma Limited Financial Information (Restated Consolidated)

Period Ended
Total Assets
Total Revenue
Profit After Tax
Net Worth
31-Mar-20
5,073.29
5,975.65
1,056.15
3,485.31
31-Mar-21
6,372.63
6,385.38
1,293.03
4,722.00
31-Mar-22
9,147.74
7,977.58
1,452.96
6,155.23
Amount in Rs. Crore

Mankind Pharma Limited IPO Details

Issue Opening Date
25 Apr-23
Issue Closing Date
27 Apr-23
Face Value
Rs.1 per share
Price
1026 to 1080 per share
Lot Size
13 Shares
Issue Size
40,058,844 shares (aggregating up to Rs.4326.36 Cr)
Offer for Sale
40,058,844 shares (aggregating up to Rs.4326.36 Cr)
Issue Type
Book Built Issue IPO
Listing At
BSE, NSE
QIB Shares Offered
50% of the Offer
NII (HNI) Shares Offered
15% of the Offer
Retail Shares Offered
35% of the Offer

Prospectus

Prospectus File

RR Investors Capital Services Pvt. Ltd AMFI-registered Mutual Fund Distributor

Head Office - 4th floor, Indraprakash Building 21, Barakhamba Road, New Delhi – 110001

LandlineLandline Number
+91 11-4444-1111

Customer Care
+91 9350316010

Security

Follow Us


SEBI Registration No: NSE Cash: INB231219636 | SEBI Registration No: NSE Derivative: INF231219636 | SEBI Registration No: BSE Cash: INB011219632 | SEBI Registration No: MCX-SX: INE261219636 | SEBI Registration No: NSE Currency: INE231219636 | SEBI Registration No: USE: INE271219631 | SEBI Registration No: CDSL: IN-DP-CDSL-3242005 | NCDEX Membership No: 00635 | MCX Membership No: 28850 | NSEL Membership No: 10650 | RBI Registration No: NBFC: N-14.03215 | IRDA Registration Number : CB-066/03 | AMFI Registration No : ARN -0032| SEBI Registration No: Merchant Banker: INM000007508


* Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing.


© 2022 RR Investors Capital Services Pvt. Ltd | All Rights Reserved.